prazosin has been researched along with Kidney Failure, Chronic in 20 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prazosin (Minipress; Pfizer), a new antihypertensive agent, was investigated in 24 outpatients with uncontrolled hypertension." | 9.04 | Prazosin in the therapy of uncontrolled hypertension. ( Lubbe, WF, 1977) |
| "Priapism developed during antihypertensive therapy with prazosin, 3-10 mg daily for 2-4 months, in two young men with severe renal failure." | 7.66 | Priapism--side-effect of prazosin in patients with renal failure. ( Pasternack, A; Ylitalo, P, 1983) |
| "Prazosin (Minipress; Pfizer), a new antihypertensive agent, was investigated in 24 outpatients with uncontrolled hypertension." | 5.04 | Prazosin in the therapy of uncontrolled hypertension. ( Lubbe, WF, 1977) |
| " In this article, doxazosin is reviewed for its efficacy in the treatment of severe essential hypertension and specific complications or conditions of mild or moderate essential hypertension, namely, left ventricular hypertrophy, hyperlipidemia, noninsulin-dependent diabetes mellitus, renal insufficiency, pheochromocytoma, chronic obstructive pulmonary disease, peripheral vascular disease, and smoking." | 4.78 | Efficacy of doxazosin in specific hypertensive patient groups. ( Taylor, SH, 1991) |
| "Priapism developed during antihypertensive therapy with prazosin, 3-10 mg daily for 2-4 months, in two young men with severe renal failure." | 3.66 | Priapism--side-effect of prazosin in patients with renal failure. ( Pasternack, A; Ylitalo, P, 1983) |
| "Terazosin is a new, long-acting, selective, postsynaptic alpha 1-adrenergic receptor antagonist with a chemical structure similar to that of prazosin." | 2.38 | Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events. ( Achari, R; Laddu, AR; Somberg, JC, 1991) |
| "Thus, functional bladder neck obstruction was considered to be responsible for obstructive voiding in these patients." | 1.29 | Functional bladder neck obstruction: a rare cause of renal failure. ( Banerjee, GK; Bhandari, M; Goel, MC; Kapoor, R; Kumar, A; Mishra, VK, 1995) |
| " After one dosage with a directly acting venodilator (nitroglycerin 5 mg s." | 1.28 | Compliance and reactivity of the peripheral venous system in chronic intermittent hemodialysis. ( Draaijer, P; Gladziwa, U; Kooman, JP; Leunissen, KM; Peltenburg, HG; Struyker-Boudier, HA; van Bortel, LM; van Hooff, JP; Wijnen, JA, 1992) |
| " The plasma half-life of terazosin in patients with normal renal function was 10." | 1.27 | Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. ( Chauveau, P; Ganeval, D; Jungers, P; Pertuiset, N, 1986) |
| "Doxazosin was not appreciably dialyzable." | 1.27 | Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. ( Bailey, RR; Begg, EJ; Carlson, RV; Cowlishaw, MG; Sharman, JR, 1986) |
| "Pharmacokinetic parameters of prazosin (t1/2, tmax, Cmax and AUC have been studied in 18 hypertensive patients with varying degrees of chronic renal failure (serum creatinine ranging from 1." | 1.27 | A pharmacokinetic study of prazosin in patients with varying degrees of chronic renal failure. ( Gordts, J; Lameire, N, 1986) |
| " The rate of absorption of prazosin was identical in the two groups (t max: I,3 +/- 0,2 h and I,6 +/- 0,4 h)." | 1.26 | [Clinical pharmacology of prazosin in arterial hypertension with chronic renal insufficiency]. ( Aubert, P; Chaignon, M; Flouvat, B; Guédon, J; Le Roux, E; Lucsko, M, 1981) |
| "Prazosin absorption was not altered in patients with impaired renal function, and there is no cumulation of the drug when given repeatedly to patients with impaired renal function." | 1.26 | Prazosin kinetics and effectiveness in renal failure. ( Affrime, MB; Hobbs, D; Lowenthal, DT; Martinez, EW; Onesti, G; Twomey, TM, 1980) |
| " The enhanced antihypertensive effect of prazosin in renal failure appears to reflect changes in the bioavailability or distribution of the drug, which result in higher drug concentrations for a given dose." | 1.26 | Responsiveness to prazosin in renal failure. ( Frost, GW; MacCarthy, EP; Monaghan, JC; Stokes, GS, 1979) |
| "Prazosin was used as an additional antihypertensive agent for treating 38 patients with hypertension and renal functional impairment." | 1.26 | Prazosin in the treatment of patients with hypertension and renal functional impairment. ( Bailey, RR, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (70.00) | 18.7374 |
| 1990's | 6 (30.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ylitalo, P | 1 |
| Pasternack, A | 1 |
| Chopra, JS | 1 |
| Parkash, C | 1 |
| Chhabra, R | 1 |
| Wadhwa, NK | 1 |
| Meltzer, VN | 1 |
| Goldberg, AP | 1 |
| Tindira, CA | 1 |
| Naumovich, AD | 1 |
| Harter, HR | 1 |
| Chaignon, M | 1 |
| Le Roux, E | 1 |
| Aubert, P | 1 |
| Lucsko, M | 1 |
| Flouvat, B | 1 |
| Guédon, J | 1 |
| Rubin, P | 1 |
| Blaschke, T | 1 |
| Lowenthal, DT | 1 |
| Hobbs, D | 1 |
| Affrime, MB | 1 |
| Twomey, TM | 1 |
| Martinez, EW | 1 |
| Onesti, G | 1 |
| Kumar, A | 1 |
| Banerjee, GK | 1 |
| Goel, MC | 1 |
| Mishra, VK | 1 |
| Kapoor, R | 1 |
| Bhandari, M | 1 |
| Lubbe, WF | 1 |
| Stokes, GS | 1 |
| Monaghan, JC | 1 |
| Frost, GW | 1 |
| MacCarthy, EP | 1 |
| Bailey, RR | 2 |
| Kooman, JP | 1 |
| Wijnen, JA | 1 |
| Draaijer, P | 1 |
| van Bortel, LM | 1 |
| Gladziwa, U | 1 |
| Peltenburg, HG | 1 |
| Struyker-Boudier, HA | 1 |
| van Hooff, JP | 1 |
| Leunissen, KM | 1 |
| Makó, J | 1 |
| Potyondi, M | 1 |
| Somberg, JC | 1 |
| Achari, R | 1 |
| Laddu, AR | 1 |
| Taylor, SH | 1 |
| Kiberd, BA | 1 |
| Jungers, P | 1 |
| Ganeval, D | 1 |
| Pertuiset, N | 1 |
| Chauveau, P | 1 |
| Carlson, RV | 1 |
| Begg, EJ | 1 |
| Cowlishaw, MG | 1 |
| Sharman, JR | 1 |
| Chin, DK | 1 |
| Ho, AK | 1 |
| Tse, CY | 1 |
| Lameire, N | 1 |
| Gordts, J | 1 |
| Kutsenko, AI | 1 |
| Zaruba, AIu | 1 |
| Arabidze, GG | 1 |
| Kukharchuk, VV | 1 |
| Mal'ginov, SV | 1 |
2 reviews available for prazosin and Kidney Failure, Chronic
| Article | Year |
|---|---|
Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.
Topics: Adrenergic alpha-Antagonists; Age Factors; Antihypertensive Agents; Dose-Response Relationship, Drug | 1991 |
Efficacy of doxazosin in specific hypertensive patient groups.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Cardiomegaly; Diabetes Mellitus, Type 2; Doxazosin | 1991 |
1 trial available for prazosin and Kidney Failure, Chronic
| Article | Year |
|---|---|
Prazosin in the therapy of uncontrolled hypertension.
Topics: Adult; Aged; Clinical Trials as Topic; Creatinine; Female; Humans; Hypertension; Hypotension, Orthos | 1977 |
17 other studies available for prazosin and Kidney Failure, Chronic
| Article | Year |
|---|---|
Priapism--side-effect of prazosin in patients with renal failure.
Topics: Adult; Glomerulonephritis; Humans; Hypertension, Renal; Kidney Failure, Chronic; Male; Prazosin; Pri | 1983 |
Prazosin in hypertension associated with chronic renal failure.
Topics: Adolescent; Adult; Follow-Up Studies; Humans; Hypertension; Kidney; Kidney Failure, Chronic; Middle | 1983 |
Effects of prazosin and propranolol on blood pressure and plasma lipids in patients undergoing chronic hemodialysis.
Topics: Adult; Blood Pressure; Cholesterol; Cholesterol, HDL; Female; Humans; Hypertension, Renal; Kidney Fa | 1984 |
[Clinical pharmacology of prazosin in arterial hypertension with chronic renal insufficiency].
Topics: Adult; Aged; Blood Pressure; Female; Heart Rate; Humans; Hypertension, Renal; Kidney Failure, Chroni | 1981 |
Prazosin protein binding in health and disease.
Topics: Adult; Blood Proteins; Erythrocytes; Female; Heart Failure; Humans; In Vitro Techniques; Kidney Fail | 1980 |
Prazosin kinetics and effectiveness in renal failure.
Topics: Adult; Aged; Blood Pressure; Blood Proteins; Dose-Response Relationship, Drug; Female; Humans; Hyper | 1980 |
Functional bladder neck obstruction: a rare cause of renal failure.
Topics: Adult; Catheters, Indwelling; Creatinine; Electromyography; Female; Follow-Up Studies; Humans; Kidne | 1995 |
Responsiveness to prazosin in renal failure.
Topics: Adult; Aged; Blood Pressure; Humans; Hypertension; Kidney Failure, Chronic; Middle Aged; Posture; Pr | 1979 |
Prazosin in the treatment of patients with hypertension and renal functional impairment.
Topics: Female; Glomerular Filtration Rate; Humans; Hypertension, Renal; Kidney Failure, Chronic; Male; Midd | 1977 |
Compliance and reactivity of the peripheral venous system in chronic intermittent hemodialysis.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Compliance; Doxazosin; Female; Humans; Hy | 1992 |
Use of Tensiomin in hypertensive patients with impaired renal function.
Topics: Adult; Captopril; Creatinine; Humans; Hydralazine; Hypertension; Kidney; Kidney Failure, Chronic; Mi | 1992 |
Effects of prazosin therapy in renal allograft recipients receiving cyclosporine.
Topics: Cyclosporins; Humans; Kidney Failure, Chronic; Kidney Transplantation; Pilot Projects; Postoperative | 1990 |
Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Female; Half-Life; Humans; Kidney Failure, Chro | 1986 |
Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Doxazosin; F | 1986 |
Neuropsychiatric complications related to use of prazosin in patients with renal failure.
Topics: Adult; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prazosin; Substance-Related Disor | 1986 |
A pharmacokinetic study of prazosin in patients with varying degrees of chronic renal failure.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Female; Half-Life; Humans; | 1986 |
[Hemodialysis in patients with incorrigible arterial hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Captopril; Female; Glomerulonephritis; Humans; Hyper | 1985 |